PTX V2
Alternative Names: PTX-V2; PTX_V2Latest Information Update: 12 Jul 2022
Price :
$50 *
At a glance
- Originator pHion Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Basal cell cancer
Most Recent Events
- 05 Jul 2022 PTX V2 is available for licensing as of 27 Jun 2022. https://www.phiontx.co.uk/partnership
- 27 Jun 2022 Preclinical trials in Basal cell cancer in United Kingdom (Parenteral) before June 2022 (phion Therapeutics website, June 2022)
- 20 Apr 2022 phion Therapeutics receives patent protection for technology in Spain